We are delighted to welcome Paul Hudson, who today starts his tenure as CEO. We also say a fond au revoir to Olivier Brandicourt, who is retiring.
Previously CEO of Novartis Pharmaceuticals (2016-2019), where he was a member of the Executive Committee, Paul has an expansive international career in healthcare that spans the U.S., Japan and Europe.
Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and most recently carried out the roles of president, AstraZeneca United States and executive vice president, North America.
He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo U.K.
“Today, I am very excited to officially join Sanofi. It is a real pleasure to be back, after almost 30 years. I am conscious that lots of things have changed. But the foundations are the same, as is the rich heritage of this company,” Paul said.
The ardent Manchester United football fan and father of three also starts a new chapter with his family, who has moved with him to Paris. French language lessons are scheduled for everyone, including Paul, who is a British national.
Paul holds a degree in economics from Manchester Metropolitan University in the U.K. and last year his alma mater awarded him an honorary Doctor of Business Administration for his achievements in industry. He also holds a diploma in marketing from the Chartered Institute of Marketing, also in the U.K.
“People are what drive me. I was drawn to healthcare so that I could positively impact people’s lives. As a leader, I firmly believe that making an impact starts within–how we do things, how we work with integrity, and how we empower and inspire each other to bring our best selves to work,” Paul says.
“Even on a tough day, I can be confident that our work has a positive impact on people–either by improving a patient’s life or by inspiring a colleague.”
Read the press release of June 7 2019: Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer